“Once again, I would like to appreciate for all your assistance during the study execution and all technical issues that Physiogenex experts helped us to understand. Physiogenex is a very strategic partner and in the future, we certainly will consider you to perform our preclinical studies.”
Recent News
- Physiogenex launches its new IgA nephropathy rat after presenting the model ASN Kidney Week 10/30/2024
- iLEADS BMS presents the effects of its novel FXR agonist in Physiogenex’s ALD/MetALD hamster models at APASL 2024, Kyoto, Japan 03/03/2024
- HepaRegenix publishes data on first in class MKK4 inhibitors demonstrating benefits in Physiogenex CCl4 mouse model of liver fibrosis 01/30/2024
- iLeads BMS publishes a new manuscript about its novel FXR agonist in Physiogenex’s obese MASH hamster and mouse models 12/04/2023
- Physiogenex to present its obese MetALD hamster model at the 7th Obesity and NASH Summit in Boston, MA, Nov. 27-29, 2023 11/23/2023
- Physiogenex to present its novel obese hamster model of MetALD at the AASLD Liver Meeting 2023 in Boston, Nov. 10-14 11/06/2023